Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haemophilus influenzae type b and meningococcal vaccine
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Haemophilus influenzae type b and meningococcal vaccine is a combination vaccine that provides protection against both Haemophilus influenzae type b (Hib) bacteria and certain groups of meningococcal bacteria (specifically groups C and Y). The vaccine works by causing the body to produce its own protection (antibodies) against these diseases. It is primarily indicated for infants and young children to prevent invasive diseases caused by these bacteria, including meningitis, pneumonia, epiglottitis, and septic arthritis. This vaccine is not a substitute for routine tetanus vaccination and will not treat symptoms of meningococcal infection or flu if already present.
- Brand names
- MenHibrix
- Other names
- Meningococcal polysaccharide vaccine and Haemophilus B conjugate vaccineHib-MenCY-TT
02
Targets
Neisseria meningitidis group C capsular polysaccharideGroup Y CPS (Neisseria meningitidis group Y capsular polysaccharide)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Haemophilus influenzae type b and meningococcal vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemophilus influenzae type b and meningococcal vaccine.